Health2Sync's innovative technology empowers patients with diabetes to take control of their health, and this public-private collaboration can further reduce the burden ...
The global self-monitoring blood glucose devices market was valued at $8,490.79 million in 2019, and is projected to reach $11,991.98 million by 2027, growing at a CAGR of 4.2% from 2020 to 2027.
Sitagliptin selectively inhibits the action of DPP-4, the primary enzyme degrading the incretin hormones, allowing glucagon-like peptide-1 and glucose-dependent insulinotropic peptide to ...